Almac Diagnostic Collaborates with Queen's University to Bring Personalized Chemotherapy for Esophageal Cancer
Shots:
- Almac Diagnostic and Queen’s University validate a test to decide the chemotherapy to be used for early-stage esophageal cancer to remove the tumor- improve prognosis and QoL
- The focus of the collaboration is to bring personalized therapies for esophageal cancer. Additionally- Almac Diagnostic has developed DNA Damage Immune Response (DDIR) Signature to personalize chemotherapy for breast cancer
- The test increases the molecular understanding of each patient’s cancer and enables the clinicians to decide the right chemotherapy to shrink the tumor
Ref: Almac Diagnostic | Image: Glassdoor
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com